Device Trial Radar · NCT07920484
A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 4, 2026
Primary completion
Jul 21, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Amber Implants B.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice. Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use. The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility. The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.
Conditions
- Vertebra Compression Fracture
Interventions
VCFix Spinal System in stand-alone configurationDevice
The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety)Time frame: 1 month
- Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)Time frame: 6 months
- Functional disability, measured by the Oswestry disability index (ODI)Time frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Montefiore Medical Center
New York, New York · Recruiting
University of Oklahoma Health Campus
Oklahoma City, Oklahoma · Not yet recruiting
Rothman Orthopaedics
Philadelphia, Pennsylvania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.